UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120

Benzinga Newsdesk www.benzinga.com Neutral 75.6%

Neg 0% Neu 75.6% Pos 0%

UBS analyst Alice Nettleton initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Buy rating and announces Price Target of $120.